Clinical Trials Logo

Fertility Risk clinical trials

View clinical trials related to Fertility Risk.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05443698 Completed - Fertility Risk Clinical Trials

SELF-GYN1 (Sonograms Enable Looking Forward- Get Your iNformation 1 Trial)

SELF-GYN1
Start date: July 25, 2022
Phase: N/A
Study type: Interventional

This clinical trial will evaluate the efficacy and safety of the use of the Turtle Health Ultrasound Scanner for the acquisition of transvaginal ultrasound images by a study participant, with no previous training, in her home when guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.

NCT ID: NCT04784325 Completed - Fertility Risk Clinical Trials

Anti-Mullerian Hormone - At My Home

AMH^2
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The AMH^2 (Anti-Mullerian Hormone - At My Home) study is a head-to-head-to-head validation study aiming to evaluate the concordance of AMH levels found in blood collected via three different routes: collected at-home using the TAP II device, drawn through standard venipuncture techniques, and collected with the ADx card, another at-home collection device widely available on the market for commercial use.

NCT ID: NCT04687189 Completed - Fertility Risk Clinical Trials

Sonograms Enable Looking Forward - Home Examinations Led by Providers Validation Study

SELF-HELP
Start date: February 27, 2021
Phase: N/A
Study type: Interventional

To demonstrate that clear, interpretable quality images of the ovaries and uterus can be generated using a portable transvaginal ultrasound scanner in the home environment, and that those images are interpretable by physicians with sufficient clarity to estimate approximate antral follicle count (i.e., appropriate for age) and to observe submucosal fibroids. Study aims to prove that images taken when ultrasound is performed by a woman herself (with HCP supervision via telemedicine) and images taken when ultrasound is administered by an HCP are of comparable quality. Study population reflects real-world patient characteristics and includes both general-population and submucosal fibroid positive controls.